Alteration in Lysophospholipids and Converting Enzymes in Glaucomatous Optic Nerves

Overview

Journal Invest Ophthalmol Vis Sci

Specialty Ophthalmology

Date 2020 Jul 1

PMID 32602905

Citations 7

Authors

Sasha M Milbeck

Sanjoy K Bhattacharya

Affiliations

Soon will be listed here.

Abstract

Purpose: To determine whether lysophospholipid (LPL) profiles and corresponding conversion enzymes in the LPL pathways are altered in the optic nerve (ON) between human control and glaucoma samples.

Methods: Lipids extracted from control (n = 11) and glaucomatous (n = 12) ON samples using the Bligh and Dyer method were subjected to high-resolution mass spectrometry on a Q-exactive mass spectrometer coupled with a high-performance liquid chromatography (Accela 600) system. Analysis was performed for LPLs (lysophosphatidylcholines, lysophosphatidylserines, lysophosphatidylethanolamines, lysophosphatidylinositols, and lysosphingomyelines) using LipidSearch v.4.1, MZmine v.2.0, and MetaboAnalyst v.4.0. LPL synthesis and degradation pathway maps, utilizing UniProt and BRENDA database entries as needed, were created using Kyoto Encyclopedia of Genes and Genomes (KEGG)-based tools. The mRNA expression level in normal and glaucomatous human ON were analyzed using Gene Expression Omnibus (GEO) entry GSE45570. Protein amounts were determined using PHAST gel and dot blot and were used for normalization of protein amounts across samples. Western blot, ELISA, and protein quantification were performed using established protocols.

Results: Principal component analysis of ON LPL profile placed control and glaucomatous ONs in two distinct separate groups. Mass spectrometric analysis of ON revealed decrease in lysophosphatidic acid, lysophosphatidylethanolamine, lysophosphatidylcholine, and significant increase in diacylglycerol in glaucomatous ON. Statistical analysis of LPL conversion enzymes revealed significant overexpression of phosphatidate phosphatase LPIN2, phospholipid phosphatase 3, phosphatidylcholine-sterol acyltransferase, and calcium-dependent phospholipase 2, and significant downregulation of glycerol-3-phosphate acyltransferase 4 at mRNA level in glaucomatous ON. Western blot and ELISA confirmed proteomic differences between normal and diseased ON.

Conclusions: Our analysis revealed alterations in specific LPL levels and corresponding select enzyme-level changes in glaucomatous ON.

Citing Articles

The Identification of New Pharmacological Targets for the Treatment of Glaucoma: A Network Pharmacology Approach.

Giuffrida E, Platania C, Lazzara F, Conti F, Marcantonio N, Drago F Pharmaceuticals (Basel). 2024; 17(10).

PMID: 39458974 PMC: 11509888. DOI: 10.3390/ph17101333.

Optimized Lipidomics Extraction of Sphingosine and Sphinganine from Optic Nerve for Signaling Studies.

Jauregui A, Neag E, Almobayed A, Lens A, Bhattacharya S Methods Mol Biol. 2024; 2816:25-33.

PMID: 38977585 DOI: 10.1007/978-1-0716-3902-3_3.

Regiospecific analysis of lipidome in the brain from mammals of land and aquatic habitats-by liquid chromatography-mass spectrometry.

Gowda S, Gowda D, Hou F, Shekhar C, Chiba H, Patzke N Heliyon. 2023; 9(12):e22959.

PMID: 38076063 PMC: 10703717. DOI: 10.1016/j.heliyon.2023.e22959.

Metabolite and Lipid Biomarkers Associated With Intraocular Pressure and Inner Retinal Morphology: 1H NMR Spectroscopy Results From the UK Biobank.

Pasquale L, Khawaja A, Wiggs J, Kim J, Hysi P, Elze T Invest Ophthalmol Vis Sci. 2023; 64(11):11.

PMID: 37552033 PMC: 10411643. DOI: 10.1167/iovs.64.11.11.

Plasma metabolite profile for primary open-angle glaucoma in three US cohorts and the UK Biobank.

Zeleznik O, Kang J, Lasky-Su J, Eliassen A, Frueh L, Clish C Nat Commun. 2023; 14(1):2860.

PMID: 37208353 PMC: 10199010. DOI: 10.1038/s41467-023-38466-w.

References

Birgbauer E, Chun J . New developments in the biological functions of lysophospholipids. Cell Mol Life Sci. 2006; 63(23):2695-701. PMC: 11136021. DOI: 10.1007/s00018-006-6155-y. View

Yun C . Lysophosphatidic Acid and Autotaxin-associated Effects on the Initiation and Progression of Colorectal Cancer. Cancers (Basel). 2019; 11(7). PMC: 6678549. DOI: 10.3390/cancers11070958. View

Ong W, Farooqui T, Kokotos G, Farooqui A . Synthetic and natural inhibitors of phospholipases A2: their importance for understanding and treatment of neurological disorders. ACS Chem Neurosci. 2015; 6(6):814-31. DOI: 10.1021/acschemneuro.5b00073. View

Fahy E, Subramaniam S, Brown H, Glass C, Merrill Jr A, Murphy R . A comprehensive classification system for lipids. J Lipid Res. 2005; 46(5):839-61. DOI: 10.1194/jlr.E400004-JLR200. View

Jiang Y, Feingold K . The expression and regulation of enzymes mediating the biosynthesis of triglycerides and phospholipids in keratinocytes/epidermis. Dermatoendocrinol. 2011; 3(2):70-6. PMC: 3117005. DOI: 10.4161/derm.3.2.14995. View

Chambers Jr W . Intraocular pressure and glaucoma. J Am Optom Assoc. 1967; 38(9):757-66. View

Goldshmit Y, Munro K, Leong S, Pebay A, Turnley A . LPA receptor expression in the central nervous system in health and following injury. Cell Tissue Res. 2010; 341(1):23-32. DOI: 10.1007/s00441-010-0977-5. View

Han X . Neurolipidomics: challenges and developments. Front Biosci. 2006; 12:2601-15. PMC: 2141543. DOI: 10.2741/2258. View

Encinas M, Milbrandt J, Johnson Jr E . Lipid rafts in neuronal signaling and function. Trends Neurosci. 2002; 25(8):412-7. DOI: 10.1016/s0166-2236(02)02215-4. View

10.

Hering H, Lin C, Sheng M . Lipid rafts in the maintenance of synapses, dendritic spines, and surface AMPA receptor stability. J Neurosci. 2003; 23(8):3262-71. PMC: 6742299. View

11.

Lloyd M, Mansberger S, Fortune B, Nguyen H, Torres R, Demirel S . Features of optic disc progression in patients with ocular hypertension and early glaucoma. J Glaucoma. 2013; 22(5):343-8. PMC: 6023854. DOI: 10.1097/IJG.0b013e31824c9251. View

12.

Iyer P, Lalane 3rd R, Morris C, Challa P, Vann R, Rao P . Autotaxin-lysophosphatidic acid axis is a novel molecular target for lowering intraocular pressure. PLoS One. 2012; 7(8):e42627. PMC: 3423407. DOI: 10.1371/journal.pone.0042627. View

13.

Chun J . Lysophospholipids in the nervous system. Prostaglandins Other Lipid Mediat. 2005; 77(1-4):46-51. DOI: 10.1016/j.prostaglandins.2004.09.009. View

14.

Benowitz L, He Z, Goldberg J . Reaching the brain: Advances in optic nerve regeneration. Exp Neurol. 2016; 287(Pt 3):365-373. DOI: 10.1016/j.expneurol.2015.12.015. View

15.

Inoue M, Xie W, Matsushita Y, Chun J, Aoki J, Ueda H . Lysophosphatidylcholine induces neuropathic pain through an action of autotaxin to generate lysophosphatidic acid. Neuroscience. 2008; 152(2):296-8. DOI: 10.1016/j.neuroscience.2007.12.041. View

16.

Crane A, Hua H, Coggin A, Gugiu B, Lam B, Bhattacharya S . Mass spectrometric analyses of phosphatidylcholines in alkali-exposed corneal tissue. Invest Ophthalmol Vis Sci. 2012; 53(11):7122-30. PMC: 3487488. DOI: 10.1167/iovs.12-10448. View

17.

Wendel A, Lewin T, Coleman R . Glycerol-3-phosphate acyltransferases: rate limiting enzymes of triacylglycerol biosynthesis. Biochim Biophys Acta. 2008; 1791(6):501-6. PMC: 2737689. DOI: 10.1016/j.bbalip.2008.10.010. View

18.

Yung Y, Stoddard N, Mirendil H, Chun J . Lysophosphatidic Acid signaling in the nervous system. Neuron. 2015; 85(4):669-82. PMC: 4400838. DOI: 10.1016/j.neuron.2015.01.009. View

19.

Fahy E, Cotter D, Sud M, Subramaniam S . Lipid classification, structures and tools. Biochim Biophys Acta. 2011; 1811(11):637-47. PMC: 3995129. DOI: 10.1016/j.bbalip.2011.06.009. View

20.

Chen Y, Kuo M, Li S, Bui H, Peake D, Sanders P . AGPAT6 is a novel microsomal glycerol-3-phosphate acyltransferase. J Biol Chem. 2008; 283(15):10048-57. PMC: 2442282. DOI: 10.1074/jbc.M708151200. View